The FDA granted priority review designation to a marketing application seeking approval of Bayer and Onyx Pharmaceuticals' Nexavar for the treatment of locally advanced or metastatic radioactive iodine -refractory differentiated thyroid cancer, the companies said Tuesday.
http://www.pharmpro.com/news/2013/08/fda-grants-priority-review-bayer-onyxs-nexavar-filing-thyroid-cancer
http://www.pharmpro.com/news/2013/08/fda-grants-priority-review-bayer-onyxs-nexavar-filing-thyroid-cancer
No comments:
Post a Comment